Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries

10+ emerging markets, Japan & ANZ transition in final phase

Venus Remedies expands global presence with marketing authorisation for enoxaparin from Azerbaijan

The company makes its maiden entry into Azerbaijan’s pharmaceutical market

FDA and EMA accept Marstacimab regulatory submissions for the treatment of Hemophilia A and B

Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting

Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873

The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe

Merck Animal Health receives positive CVMP opinion for an injectable formulation of Bravecto

The CVMP recommends the product for approval for the treatment and persistent killing of fleas

Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug

Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya

Biocon Biologics completes Integration of Viatris' Biosimilar business

The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone

CPHI & PMEC India 2023 redefines pharma landscape

South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries

Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial

Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta